Inhibiteurs sélectifs de la recapture de la sérotonine (ISRS) et ostéoporose
| Autor: | Fétique-Will, Anne-Catherine, Chevalley, Thierry, Rizzoli, René |
|---|---|
| Jazyk: | francouzština |
| Rok vydání: | 2011 |
| Předmět: |
endocrine system
Evidence-Based Medicine Depression/drug therapy Risk Factors mental disorders digestive oral and skin physiology ddc:618.97 Humans Bone Density/drug effects Serotonin Uptake Inhibitors/administration & dosage/adverse effects behavioral disciplines and activities Osteoporosis/chemically induced/prevention & control |
| Zdroj: | Revue médicale suisse, Vol. 7, No 299 (2011) pp. 1299-304 |
| ISSN: | 1660-9379 |
| Popis: | Selective serotonin reuptake inhibitors (SSRI) represent the first-line treatment of depression. Several studies demonstrate that use of therapeutical doses of SSRI is associated with a decreased bone mineral density (BMD) and an increased risk of fracture. Mechanisms of action of SSRI on bone tissue are not totally clarified. These treatments would be associated with an increased risk of falls and would also have a direct effect on bone metabolism. Regarding proofs existing of the implication of SSRI on osteoporosis, while waiting for larger-scale prospective studies, it appears reasonable that practitioners assess bone loss within risk groups of patients treated with SSRI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|